Drug Trial Radar · NCT05484193
GnRH Agonist for Luteal Phase Support.
Last checked: Nov 20, 2026Latest source record: Aug 2, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
150
Actual
Start
Jun 8, 2020
Primary completion
Apr 15, 2022
Study completion Jan 1, 2023
Sponsor
- Lead sponsor
- Shaare Zedek Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 2, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Objective To assess the the efficacy of luteal support with GnRH agonist in patients undergoing IVF in antagonist-based hcg triggered cycles compared with standard luteal support with progesterone. Design prospective randomized controled study Subjects Patients who underwent antagonist-based cycles performed in the "Shaare Zedek Medical Center" IVF clinic between 2020 and 2022 Intervention Intranasal GnRH-agonist or vaginal Progesterone for luteal support. Main outcome measures Pregnancy and clinical pregnancy rates, ohss. The study cohort included 150 patients who underwent 164 cycles. A total of 127 cycles were included. Of them, 64 were treated with GnRH-a and 63 with progesterone. Hypothesis: This RCT suggests that GnRH-a for luteal phase support is associated with a higher positive β-hCG pregnancy rate and clinical pregnancy rate, compared with standard progesterone support in an antagonist-based protocol triggered with hCG, while maintaining a similar safety profile.
Conditions
- Use of GnRH Agonist Alone for Luteal Phase Support in Fresh IVF Cycles
Interventions
GnRH agonistDrug
GnRH agonist alone for luteal phase support in fresh IVF embryo transfer cycles
ProgesteroneDrug
vaginal progesterone for luteal phase support
Primary outcomes
What the sponsor says the trial is designed to measure.
- pregnancyTime frame: 2 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shaare Zedek medical Center
Jerusalem, Israel
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.